(Adnkronos) – Takeda has announced new results from the Phase 4 Verdict study, the first prospective, randomized trial to evaluate a treat-to-target approach aimed at achieving disease clearance in ulcerative colitis, a therapeutic goal that integrates symptomatic, endoscopic, and histological remission in